证券代码：600276 证券简称：恒瑞医药 公告编号：临 2026-044 江苏恒瑞医药股份有限公司 第九届董事会第二十四次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 江苏恒瑞医药股份有限公司（以下简称"公司"）第九届董事会第二十四次 会议于 2026 年 3 月 25 日以现场结合通讯方式召开。本次会议应到董事 11 人， 实到董事 11 人。会议召开符合《公司法》《公司章程》的规定。公司全体董事认 真审议并通过以下议案： 一、《公司 2025 年度董事会工作报告》 赞成：11 票 反对：0 票 弃权：0 票 二、《公司 2025 年年度报告》 同意按中国境内相关法律法规要求编制的本公司 2025 年年度报告全文及摘 要（详见上海证券交易所网站：http://www.sse.com.cn）。同意按《香港联合交 易所有限公司证券上市规则》等要求编制的本公司 2025 年年度报告及 2025 年年 度业绩公告。 赞成：11 票 反对：0 票 弃权：0 票 本议案已经公司董事会审计委员会审议通过。 三、《公司 2 ...

Financial Performance - The total operating revenue for 2025 reached ¥31.63 billion, an increase of 13.02% compared to ¥27.98 billion in 2024[22]. - The total profit for the year was ¥8.71 billion, reflecting a growth of 21.45% from ¥7.17 billion in the previous year[22]. - The net profit attributable to shareholders was ¥7.71 billion, up 21.69% from ¥6.34 billion in 2024[22]. - The net profit after deducting non-recurring gains and losses was ¥7.41 billion, a 20.00% increase from ¥6.18 billion in 2024[22]. - Cash flow from operating activities amounted to ¥11.24 billion, representing a significant increase of 51.36% compared to ¥7.42 billion in 2024[22]. - The net assets attributable to shareholders at the end of 2025 were ¥61.27 billion, a 34.61% increase from ¥45.52 billion at the end of 2024[22]. - Total assets at the end of 2025 reached ¥69.87 billion, marking a 39.36% increase from ¥50.14 billion in 2024[22]. - Basic earnings per share increased by 19.00% to CNY 1.19 in 2025 from CNY 1.00 in 2024[24]. - The company reported a net cash flow from operating activities of CNY 4.810 billion in the third quarter of 2025[28]. - The company reported a significant increase in financing activities, with net cash flow from financing activities rising by 601.85% to ¥7.78 billion, primarily due to the issuance of H shares[158]. Research and Development - The company has a diverse R&D pipeline in oncology, metabolic and cardiovascular diseases, and neuroscience, focusing on unmet clinical needs[36]. - The company aims to develop multi-target therapies and combination sequential therapies to achieve high response rates and long-lasting efficacy[37]. - The company has established a comprehensive electronic project management platform that covers the entire drug development cycle, from target discovery to real-world data presentation[40]. - The company has submitted IND applications for several candidates after thorough preclinical validation, indicating a strong commitment to regulatory compliance[42]. - The company is actively conducting clinical trials at qualified medical institutions, ensuring adherence to GCP standards and monitoring product safety and efficacy[42]. - The company has a structured approach to clinical trial design and management, ensuring high data quality and regulatory compliance throughout the process[42]. - The company has established a comprehensive quality management policy covering all aspects of raw material procurement and production, ensuring compliance with GMP standards[46]. - The company has implemented a digital supplier relationship management system to manage the entire lifecycle of raw material procurement[46]. - The company has a strong emphasis on research in oncology, metabolic and cardiovascular diseases, and neuroscience, with a significant number of candidates targeting these areas[38]. - The company has 28 self-developed innovative molecules entering clinical stages, covering various disease treatment areas including oncology and chronic diseases[80]. Product Development and Pipeline - The company has a robust pipeline with a healthy cycle of products in various stages of development, ensuring a continuous flow of innovative solutions[184]. - The company is developing multiple drug candidates targeting various conditions, including SHR-1819 for chronic spontaneous urticaria and SHR-1139 for ulcerative colitis, both in China[119]. - The company is focusing on expanding its oncology portfolio with several combination therapies in development, including those targeting PD-L1 and HER2[102]. - The company is developing new formulations, such as oral GLP-1 for obesity and injectable GLP-1 for type 2 diabetes[101]. - The company is exploring treatments for autoimmune diseases, with candidates like SHR-2173 for lupus nephritis and systemic lupus erythematosus[103]. - The company is targeting rare diseases with specific therapies, including HRS-5965 for IgA nephropathy[102]. - The company is committed to addressing unmet medical needs in pediatric populations with drugs like SHR-1819 for atopic dermatitis[102]. - The company is leveraging advanced technologies in drug development, including ADCs (antibody-drug conjugates) for targeted cancer therapies[102]. - The company has multiple ongoing clinical trials for innovative drugs targeting various cancers, including HER2-positive metastatic breast cancer and advanced non-small cell lung cancer[107]. - The company is developing a combination therapy for first-line treatment of small cell lung cancer and advanced liver cancer, with trials ongoing in China[108]. Market Expansion and Strategy - The company is committed to global expansion and exploring innovative international cooperation models to benefit patients worldwide[50]. - The company is actively pursuing market expansion strategies in China, focusing on innovative therapies for chronic and complex diseases[101]. - The company is exploring opportunities for market expansion and potential mergers and acquisitions to strengthen its position in the pharmaceutical industry[58]. - The company has established a clinical research and collaboration center in Boston, USA, and has initiated multiple overseas clinical trials across Phases I to III[85]. - The company has completed 12 overseas business expansion transactions in 2023, with a potential total transaction value exceeding $27 billion, enhancing its global influence and industry recognition[153]. - The company is actively exploring partnerships with leading global pharmaceutical companies to maximize the commercial value of its products[153]. - The company is committed to aligning its strategies with national policies that promote innovation and support for new drug development[60]. - The company has received approval for multiple new drugs targeting various cancers, including HER2-positive breast cancer and advanced non-small cell lung cancer (NSCLC) with specific genetic mutations[54]. - The company is expanding its product line with new treatments for chemotherapy-induced nausea and vomiting, targeting patients undergoing highly emetogenic chemotherapy[54]. - The company is focusing on enhancing patient outcomes through targeted therapies and personalized medicine approaches in oncology[55]. Regulatory and Compliance - The company has successfully passed compliance management system certifications, becoming one of the first in the pharmaceutical industry to achieve this[73]. - The company has received over 70 regulatory designations for expedited pathways, including 9 from the US and Europe, enhancing its global clinical trial capabilities[146]. - The company has submitted 15 new drug/new indication applications (NDA/BLA) during the reporting period, indicating a strong pipeline of innovative products[126]. - The company has published 1,027 peer-reviewed papers in top international journals, with a cumulative impact factor of approximately 8,043 during the reporting period[126]. - The company has established a strong end-to-end clinical development capability, covering over 5,000 clinical researchers and conducting more than 400 clinical trials for over 100 innovative drugs[145]. Talent and Organizational Development - The company successfully recruited 660 core talents by 2025, with over 200 holding master's or doctoral degrees from renowned institutions, significantly enhancing its international and high-potential talent reserve[94]. - The company is committed to building a global talent pipeline through systematic campus recruitment projects, increasing the proportion of talents with overseas education backgrounds[94]. - The company has launched various employee activities and leadership forums to strengthen corporate culture and enhance organizational cohesion[96]. - The company is focused on accelerating internal talent development through targeted training programs for different levels of key personnel[94]. - The company has established a dual-channel career development and long-term incentive plan to reward high performers continuously[96]. Industry Trends and Challenges - The pharmaceutical industry in China is characterized by high investment, high risk, and strict regulation, with rapid growth driven by increasing healthcare demand and aging population[58]. - The competitive landscape in the pharmaceutical industry remains challenging, with increasing market saturation and the need for differentiation in product offerings[58]. - The government has emphasized the importance of the biopharmaceutical industry, implementing policies to support innovation and high-quality development in the sector[59]. - The demand for innovative treatment solutions in metabolic disorders is increasing due to the need for better efficacy and safety profiles[132]. - The global dementia patient population is estimated to be 58.3 million in 2023, with Alzheimer's disease accounting for 60% to 70% of these cases, highlighting a critical need for disease-modifying therapies[136].

江苏恒瑞医药股份有限公司 2025 年度利润分配方案及提请股东会授权董事会 制定 2026 年中期分红方案的公告 证券代码：600276 证券简称：恒瑞医药 公告编号：临 2026-048 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例：每股派发现金股利 0.2 元（含税）。 本次利润分配股本以分红派息登记日股本（扣除公司股份回购专用证券 账户持有股数）为基数，具体日期将在权益分派实施公告中明确。 在实施权益分派的股权登记日前公司总股本发生变动的，拟维持每股分 配比例不变，相应调整分配总额，并将另行公告具体调整情况。 公司董事会提请股东会授权董事会根据股东会决议在符合利润分配的条 件下制定其他具体的 2026 年中期分红方案。 本年度现金分红比例低于 30%的简要原因说明：第一，公司所处行业为 医药行业，医药行业具有高投入、高风险、创新药研发周期长且成本高昂的特性， 尤其是公司目前正处于仿制药向创新药转型的关键阶段，需大量资金投入国内外 临床试验及创新药研发；第二，公司目前正在广东、北京、天津等地 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Jiangsu Hengrui Pharmaceuticals Co., Ltd. 江蘇恒瑞醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1276） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 孫飄揚先生 中國上海 2026年3月20日 於本公告日期，董事會成員包括(i)執行董事孫飄揚先生、戴洪斌先生、馮佶女 士、張連山先生、江寧軍先生及孫杰平先生；(ii)非執行董事郭叢照女士；及(iii) 獨立非執行董事董家鴻先生、曾慶生先生、孫金雲先生及周紀恩先生。 证券代码：600276 证券简称：恒瑞医药 公告编号：临 2026-043 江苏恒瑞医药股份有限公司 关于获得药物临床试验批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，江苏恒瑞医 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 孫飄揚先生 Jiangsu Hengrui Pharmaceuticals Co., Ltd. 江蘇恒瑞醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1276） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的有關法例規定，江蘇恒瑞醫藥股份有限公司（「本公司」）在 上海證券交易所網站( www.sse.com.cn )刊發了以下公告。茲載列如下，僅供參閱。 承董事會命 江蘇恒瑞醫藥股份有限公司 董事長 中國上海 2026年3月20日 於本公告日期，董事會成員包括(i)執行董事孫飄揚先生、戴洪斌先生、馮佶女 士、張連山先生、江寧軍先生及孫杰平先生；(ii)非執行董事郭叢照女士；及(iii) 獨立非執行董事董家鴻先生、曾慶生先生、孫金雲先生及周紀恩先生。 近日，江苏恒瑞医药股份有限公司（以下简称"公司"）子公司苏州盛迪亚 生物 ...

一、药物的基本情况 药物名称：SHR-3836 注射液 证券代码：600276 证券简称：恒瑞医药 公告编号：临 2026-043 江苏恒瑞医药股份有限公司 关于获得药物临床试验批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，江苏恒瑞医药股份有限公司（以下简称"公司"）子公司上海恒瑞医 药有限公司收到国家药品监督管理局（以下简称"国家药监局"）核准签发关于 SHR-3836 注射液的《药物临床试验批准通知书》，将于近期开展临床试验。现 将相关情况公告如下： SHR-3836 注射液是公司自主研发的创新型抗肿瘤药物，拟用于治疗多发性 骨髓瘤。经查询，目前国内外尚无同类药上市。截至目前，SHR-3836 注射液相 关项目累计研发投入约 3,170 万元(未经审计)。 三、风险提示 根据我国药品注册相关的法律法规要求，药物在获得药物临床试验批准通知 书后，尚需开展临床试验并经国家药监局审评、审批通过后方可生产上市。药品 从研制、临床试验报批到投产的周期长、环节多，药品研发及至上市容易受到一 些不确定性因素的影 ...

证券代码：600276 证券简称：恒瑞医药 公告编号：临 2026-042 江苏恒瑞医药股份有限公司 关于获得药品注册批准的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，江苏恒瑞医药股份有限公司（以下简称"公司"）子公司苏州盛迪亚 生物医药有限公司收到国家药品监督管理局（以下简称"国家药监局"）的通知， 批准公司自主研发的 1 类创新药注射用瑞康曲妥珠单抗（SHR-A1811）新增适应 症。现将相关情况公告如下： 一、药品的基本情况 药品名称：注射用瑞康曲妥珠单抗 剂型：注射剂 规格：0.1g/瓶 注册分类：治疗用生物制品 2.2 类 受理号：CXSS2500094 处方药/非处方药：处方药 批准的适应症：本品适用于治疗既往接受过一种或一种以上抗 HER2 药物治 疗的局部晚期或转移性 HER2 阳性成人乳腺癌患者。 二、药品的已获批适应症情况 公司注射用瑞康曲妥珠单抗已于 2025 年 5 月在国内获批上市，适用于治疗 存在 HER2（ERBB2）激活突变且既往接受过至少一种系统治疗的不可切除的局 部晚期或转移 ...

（於中華人民共和國註冊成立的股份有限公司） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 （股份代號：1276） Jiangsu Hengrui Pharmaceuticals Co., Ltd. 江蘇恒瑞醫藥股份有限公司 承董事會命 江蘇恒瑞醫藥股份有限公司 董事長 孫飄揚先生 中國上海 2026年3月16日 於本公告日期，董事會成員包括(i)執行董事孫飄揚先生、戴洪斌先生、馮佶女 士、張連山先生、江寧軍先生及孫杰平先生；(ii)非執行董事郭叢照女士；及(iii) 獨立非執行董事董家鴻先生、曾慶生先生、孫金雲先生及周紀恩先生。 证券代码：600276 证券简称：恒瑞医药 公告编号：临 2026-041 海外監管公告 江苏恒瑞医药股份有限公司 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的有關法例規定，江蘇恒瑞醫藥股份有限公司（「本公司」）在 上海證券交易所網站( www.sse.com.cn )刊發了以下 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Jiangsu Hengrui Pharmaceuticals Co., Ltd. 江蘇恒瑞醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1276） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的有關法例規定，江蘇恒瑞醫藥股份有限公司（「本公司」）在 上海證券交易所網站( www.sse.com.cn )刊發了以下公告。茲載列如下，僅供參閱。 承董事會命 江蘇恒瑞醫藥股份有限公司 董事長 孫飄揚先生 中國上海 2026年3月16日 於本公告日期，董事會成員包括(i)執行董事孫飄揚先生、戴洪斌先生、馮佶女 士、張連山先生、江寧軍先生及孫杰平先生；(ii)非執行董事郭叢照女士；及(iii) 獨立非執行董事董家鴻先生、曾慶生先生、孫金雲先生及周紀恩先生。 证券代码：600276 证券简称：恒瑞医药 公告编号：临 2026-04 ...

证券代码：600276 证券简称：恒瑞医药 公告编号：临 2026-041 江苏恒瑞医药股份有限公司 关于获得药物临床试验批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 SHR-1905 注射液是胸腺基质淋巴细胞生成素（TSLP）单克隆抗体，可以阻 断炎症细胞因子的释放，抑制下游炎症信号的传导，最终改善炎症状态并控制疾 病进展。目前,全球有同类产品 Tezepelumab（安进/阿斯利康，商品名 TEZSPIRE） 获批上市。经查询 EvaluatePharma 数据库，2025 年 Tezepelumab 全球销售额约 为 19.36 亿美元。截至目前，SHR-1905 注射液相关项目累计研发投入约 25,710 万元（未经审计）。 三、风险提示 根据我国药品注册相关的法律法规要求，药物在获得药物临床试验批准通知 书后，尚需开展临床试验并经国家药监局审评、审批通过后方可生产上市。药品 从研制、临床试验报批到投产的周期长、环节多，药品研发及至上市容易受到一 些不确定性因素的影响，敬请广大投资者谨慎决策，注意防 ...